Literature DB >> 11379049

Effect of the antianginal drug bepridil on intracellular Ca2+ release and extracellular Ca2+ influx in human neutrophils.

L W Chen1, C R Jan.   

Abstract

To understand more fully the effects of bepridil, an antiarrhythmic and antianginal drug, on myocardial ischemia-reperfusion injury and systemic immune responses, its effect on intracellular Ca2+ levels ([Ca2+]i) in human neutrophils was investigated by using fura-2 as a fluorescent probe. Bepridil (10-200 microM) increased [Ca2+]i in a concentration-dependent fashion. This signal was partly inhibited by removal of extracellular Ca2+. In a Ca(2+)-free medium, pretreatment with bepridil (100 microM) abolished the Ca2+ release induced by thapsigargin (1 microM), an endoplasmic reticulum Ca2+ pump inhibitor, and by carbonylcyanide m-chlorophenylhydrazone (2 microM), a mitochondrial uncoupler. Pretreatment with carbonylcyanide m-chlorophenylhydrazone and thapsigargin, respectively, partly inhibited bepridil-induced Ca2+ release. Addition of Ca2+ (3 mM) increased [Ca2+]i after pretreatment with bepridil (100 microM) in a Ca(2+)-free medium. Bepridil (100 microM)-induced Ca2+ release was not altered when phospholipase C was inhibited by U73122 (2 microM). Both Ca2+ release and Ca2+ entry induced by bepridil (100 microM) were augmented by activating protein kinase C with phorbol 12-myristate 13-acetate (10 nM), and were suppressed by inhibiting protein kinase C with GF 109203X (2 microM). Treatment with bepridil (10-20 microM) for 30 min increased the production of reactive oxygen intermediates (ROI) by more than 50%. Collectively, it was found that bepridil increased [Ca2+]i concentration-dependently in human neutrophils by releasing Ca2+ from the endoplasmic reticulum, mitochondria and, possibly, other compartments in a phospholipase C-independent manner. Bepridil also activated Ca2+ influx. The activity of protein kinase C may regulate bepridil-induced Ca2+ release and Ca2+ entry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11379049     DOI: 10.1016/s1567-5769(01)00031-5

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  2 in total

1.  Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.

Authors:  Stefano Baldoni; Beatrice Del Papa; Erica Dorillo; Patrizia Aureli; Filomena De Falco; Chiara Rompietti; Daniele Sorcini; Emanuela Varasano; Debora Cecchini; Tiziana Zei; Ambra Di Tommaso; Emanuela Rosati; Gabriela Alexe; Giovanni Roti; Kimberly Stegmaier; Mauro Di Ianni; Franca Falzetti; Paolo Sportoletti
Journal:  Int J Cancer       Date:  2018-03-23       Impact factor: 7.396

2.  Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.

Authors:  See-Hyoung Park; Young Min Chung; Jessica Ma; Qin Yang; Jonathan S Berek; Mickey C-T Hu
Journal:  Oncotarget       Date:  2016-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.